• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

    1/11/22 8:00:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRDF alert in real time by email

    SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs.

    Cardiff Oncology is a clinical-stage biotechnology company and our mission is to develop new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Our investigational drug, onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, is being evaluated in combination with standard-of-care chemotherapy and targeted therapeutics. We are assessing tumor genomics and using our expertise in biomarker technology to rapidly evaluate patient response to treatment. (PRNewsfoto/Cardiff Oncology, Inc.)

    "We are excited to welcome Tod and Charles to Cardiff Oncology as we approach key inflection points in onvansertib's development," said Mark Erlander, Ph.D., chief executive officer of Cardiff Oncology. "Tod has a wealth of expertise and experience bringing targeted, first-of-their-kind cancer therapeutics from preclinical development to launch, and Charles brings a valuable perspective on regulatory pathways to approval of novel cancer drugs through his vast experience in the pharmaceutical industry. We're grateful to have their deep understanding of the oncology landscape in which we intend to advance onvansertib, so that we can maximize its success as we work to improve treatment options and outcomes for patients with historically difficult-to-treat cancers."

    Dr. Smeal added, "Onvansertib's ability to sensitize cancer cells to currently available therapeutic agents give this versatile molecule immense potential to close gaps in a wide range of oncology treatment regimens. I am eager to begin working to advance Cardiff Oncology's clinical pipeline and look forward to leading our efforts to enable its expansion into additional indications."

    Mr. Monahan commented, "Cardiff Oncology's robust clinical dataset demonstrates the potential of onvansertib in combination with standard-of-care therapy to add significant clinical benefit across a number of cancer indications. I am thrilled to have the opportunity to lead our efforts through the regulatory process and will work with my new colleagues to advance onvansertib towards registration as expeditiously as possible."

    Appointee Bios

    Dr. Smeal joins Cardiff Oncology following roles as chief scientific officer at Hexagon Bio, chief scientific officer of Cancer Biology at Eli Lilly and Company, director of the Oncology Research Unit of Pfizer, and senior group leader at the SUGEN site of Pharmacia and Upjohn and SUGEN. With over 20 years in industry working on targeted therapies, Dr. Smeal has played key leadership roles in delivering about 20 first-in-human drugs/new medical entities and several FDA-approved or soon-to-be approved drugs, including Lorbrena, Xalkori, Vizimpro and Nirogacestat. Dr. Smeal's work in developing cancer therapies has been focused on intracellular signaling, kinases, drug pharmacology, and targeted therapies and their resistance mechanisms. Prior to his career in industry, Dr. Smeal was a post-doctoral fellow of the American Cancer Society and a senior post-doctoral fellow of the MIT-Merck fellowship program. Dr. Smeal holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biology from the University of California, San Diego.

    Mr. Monahan joins Cardiff Oncology following a role as the global head of regulatory affairs for Erytech PharmaSA, where he led the regulatory strategy and execution of the company's lead asset across multiple oncology indications in both the United States and Europe. Prior to Erytech, Mr. Monahan held senior regulatory positions at several pharmaceutical companies including Millennium Pharmaceuticals, Molecular Insight Pharmaceuticals, AVEO Pharmaceuticals, and Transgene SA. In these roles, he worked on projects covering all stages of drug development, from preclinical through post-commercialization. Mr. Monahan is a registered pharmacist with extensive experience in clinical pharmacy, healthcare management, and pharmaceutical development and has over 20 years of regulatory experience developing drugs and biologics for oncology, infectious diseases, and ocular indications. He holds a B.S. in pharmacy from the University of Rhode Island and a M.S. in regulatory affairs and health policy from the Massachusetts College of Pharmacy and Health Sciences. 

    Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    In connection with Dr. Smeal joining Cardiff Oncology, the Company's Board of Directors approved the grant of non-qualified stock options to purchase 275,088 shares of Cardiff Oncology common stock outside of the Cardiff Oncology 2021 Omnibus Equity Incentive Plan. The stock option was granted as an inducement material to Dr. Smeal becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The option was granted as of January 10, 2022, and has an exercise price of $6.58 per share, the closing price on the grant date. The option vests over four years with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to Dr. Smeal's continued employment with Cardiff Oncology on such vesting dates.

    About Cardiff Oncology, Inc.

    Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 ("PLK1") inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to refine assessment of patient response to treatment. We have three clinical programs currently ongoing: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC); and a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castrate-resistant prostate cancer (mCRPC). For more information, please visit https://www.cardiffoncology.com.  

    Forward-Looking Statements

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

    Cardiff Oncology Contact:

    Vicki Kelemen

    Chief Operating Officer

    858-952-7652

    [email protected] 

    Investor Contact:

    Joyce Allaire

    LifeSci Advisors

    212-915-2569

    [email protected] 

    Media Contact:

    Amy Jobe, Ph.D.

    LifeSci Communications

    315-879-8192

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-appoints-tod-smeal-phd-as-chief-scientific-officer-and-charles-monahan-rph-as-senior-vice-president-regulatory-affairs-301458077.html

    SOURCE Cardiff Oncology, Inc.

    Get the next $CRDF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRDF

    DatePrice TargetRatingAnalyst
    9/6/2024$8.00Buy
    Craig Hallum
    2/28/2022$26.00 → $25.00Buy
    HC Wainwright & Co.
    1/5/2022Outperform
    William Blair
    12/8/2021$19.00Outperform
    Robert W. Baird
    12/8/2021$19.00Outperform
    Baird
    8/10/2021$25.00 → $26.00Buy
    HC Wainwright & Co.
    8/9/2021$30.00 → $20.00Buy
    Maxim Group
    More analyst ratings

    $CRDF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the United States Patent and Trademark Office (USPTO) has issued to Cardiff Oncology U.S. patent No. 12,263,173 with an expected expiration date of no earlier than 2043. The claims of the patent cover the method of using onvansertib in combination with bevacizumab (bev) in any line of therapy for the treatment of metastatic colorectal cancer (mCRC) patients who have not previously been treated with bev. "The expansion of our intellectual property portfolio strategical

      4/23/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $2.79 per share, which is equal to the closing price of Cardiff Oncology's common stock on April 14, 2025. Each option

      4/15/25 4:10:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Kabbinavar Fairooz

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      3/13/25 4:06:04 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Levine James E.

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      3/13/25 4:05:04 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Smeal Tod

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      3/13/25 4:03:03 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

      First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q

      5/4/23 4:10:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

      Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib  Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as

      2/2/23 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

      SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs. "We are excited to welcome Tod and Charles to Cardiff Oncology as we approach key in

      1/11/22 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Levine James E. bought $36,726 worth of shares (7,716 units at $4.76) (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/18/24 4:37:28 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Tannenbaum Renee P bought $34,224 worth of shares (10,000 units at $3.42), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/16/24 5:00:03 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Pace Gary W bought $940,199 worth of shares (361,615 units at $2.60), increasing direct ownership by 50% to 1,047,876 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/12/24 4:05:04 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Financials

    Live finance-specific insights

    See more
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

      SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors

      2/20/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

      - Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm - - In the experimental arms, 30mg dose of onvansertib demonstrated a higher ORR compared to 20mg dose of onvansertib (64% vs. 50%) with deeper tumor regression in the 30mg arm - - Onvansertib was well tolerated at both doses - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - - Company will hold a conference call today at 8:00 a.m. ET / 5:00 a.m. PT - SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology co

      12/10/24 6:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/6/24 4:01:34 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/14/23 12:47:09 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cardiff Oncology Inc.

      SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)

      1/26/23 1:30:22 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Cardiff Oncology with a new price target

      Craig Hallum initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $8.00

      9/6/24 7:59:22 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cardiff Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $25.00 from $26.00 previously

      2/28/22 7:10:55 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Cardiff Oncology

      William Blair initiated coverage of Cardiff Oncology with a rating of Outperform

      1/5/22 8:00:11 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    SEC Filings

    See more
    • Amendment: SEC Form S-3/A filed by Cardiff Oncology Inc.

      S-3/A - Cardiff Oncology, Inc. (0001213037) (Filer)

      5/8/25 4:13:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

      5/8/25 4:10:08 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Cardiff Oncology Inc.

      10-Q - Cardiff Oncology, Inc. (0001213037) (Filer)

      5/8/25 4:00:18 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care